PT2782598T - Proteínas recombinantes e suas utilizações terapêuticas - Google Patents

Proteínas recombinantes e suas utilizações terapêuticas

Info

Publication number
PT2782598T
PT2782598T PT128247053T PT12824705T PT2782598T PT 2782598 T PT2782598 T PT 2782598T PT 128247053 T PT128247053 T PT 128247053T PT 12824705 T PT12824705 T PT 12824705T PT 2782598 T PT2782598 T PT 2782598T
Authority
PT
Portugal
Prior art keywords
recombinant proteins
therapeutic uses
therapeutic
recombinant
proteins
Prior art date
Application number
PT128247053T
Other languages
English (en)
Original Assignee
In3Bio Ltd Codan Services Ltd
Charlton Keith Alan
Dhondt Erik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In3Bio Ltd Codan Services Ltd, Charlton Keith Alan, Dhondt Erik filed Critical In3Bio Ltd Codan Services Ltd
Publication of PT2782598T publication Critical patent/PT2782598T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT128247053T 2011-11-23 2012-11-21 Proteínas recombinantes e suas utilizações terapêuticas PT2782598T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563128P 2011-11-23 2011-11-23
US201261654401P 2012-06-01 2012-06-01

Publications (1)

Publication Number Publication Date
PT2782598T true PT2782598T (pt) 2020-09-02

Family

ID=47716105

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128247053T PT2782598T (pt) 2011-11-23 2012-11-21 Proteínas recombinantes e suas utilizações terapêuticas

Country Status (22)

Country Link
US (3) US9902760B2 (pt)
EP (2) EP3744343A1 (pt)
JP (4) JP6121436B2 (pt)
KR (2) KR102274211B1 (pt)
CN (3) CN108864291A (pt)
AU (3) AU2012342117B2 (pt)
BR (1) BR112014012460B1 (pt)
CA (1) CA2856255C (pt)
DK (1) DK2782598T3 (pt)
ES (1) ES2812564T3 (pt)
HR (1) HRP20201282T1 (pt)
HU (1) HUE050438T2 (pt)
IL (2) IL232645B (pt)
LT (1) LT2782598T (pt)
MX (1) MX354902B (pt)
MY (2) MY184576A (pt)
PL (1) PL2782598T3 (pt)
PT (1) PT2782598T (pt)
RS (1) RS60782B1 (pt)
RU (2) RU2650574C2 (pt)
SI (1) SI2782598T1 (pt)
WO (1) WO2013076580A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864291A (zh) * 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
IL300235A (en) * 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
CN113214410A (zh) * 2017-11-04 2021-08-06 海南大学 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
US20210393768A1 (en) * 2018-08-27 2021-12-23 University Of Virginia Patent Foundation Compositions and methods for preventing and treating virus infection
BR112021026132A2 (pt) * 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
JP2023500889A (ja) 2019-11-07 2023-01-11 イン３バイオ・リミテッド 非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物
CN112574309B (zh) * 2019-12-05 2023-06-16 启愈生物技术(上海)有限公司 一种抗pd-l1纳米抗体及其用途
WO2021195327A1 (en) * 2020-03-25 2021-09-30 The Regents Of The University Of Colorado, A Body Corporate Bivalent egf fusion toxins
CN113735980A (zh) * 2021-08-23 2021-12-03 中国医学科学院北京协和医院 一种自融合串联蛋白修饰方法及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
EP1030684A4 (en) * 1997-11-14 2004-09-15 Euro Celtique Sa MODIFIED ANTIBODIES WITH IMPROVED CAPACITY TO TRIGGER ANTI-IDIOTYPE RESPONSE
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US7078486B2 (en) * 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
AU2001249372A1 (en) * 2000-03-23 2001-10-03 Greenville Hospital System Bi-functional cancer treatment agents
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
CA2447585A1 (en) * 2001-05-14 2003-01-23 Duotol Ab Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2457143A1 (en) 2001-08-17 2003-02-27 Roger Williams Hospital In situ immunization
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CN1665931A (zh) * 2002-05-31 2005-09-07 西根控股有限公司 从膜转运序列衍生的自身聚集或自身团聚嵌合蛋白
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社ＡＭＢｉＳ ヘテロ型５量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP2008536479A (ja) * 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
FR2882654B1 (fr) * 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
CN1686562A (zh) * 2005-03-31 2005-10-26 南京大学 一种转铁蛋白与生物还原剂的结合物及其制备方法
WO2007089871A2 (en) * 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
DE602006015421D1 (de) * 2006-04-13 2010-08-26 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh HER-2/neu Multipeptidimpfstoff
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
JP2009543071A (ja) * 2006-07-06 2009-12-03 モレキュラー ロジックス，インコーポレイテッド ドミナントネガティブリガンド薬物発見システム
CA2661634C (en) * 2006-09-06 2017-03-28 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CN1995064A (zh) * 2006-12-20 2007-07-11 李欣越 增强生物活性的长效重组人红细胞生长因子融合蛋白及方法
US7786267B2 (en) * 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2115002B1 (en) * 2007-02-02 2014-08-20 Baylor Research Institute Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP2011187653A (ja) 2010-03-08 2011-09-22 Olympus Corp 防水機器
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN108864291A (zh) * 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途

Also Published As

Publication number Publication date
US9902760B2 (en) 2018-02-27
RU2766595C2 (ru) 2022-03-15
IL232645B (en) 2021-01-31
RU2018108421A3 (pt) 2021-06-04
ES2812564T3 (es) 2021-03-17
RS60782B1 (sr) 2020-10-30
JP6953467B2 (ja) 2021-10-27
AU2020201297B2 (en) 2022-03-10
RU2014124923A (ru) 2015-12-27
BR112014012460A2 (pt) 2017-06-06
MX354902B (es) 2018-03-23
AU2012342117B2 (en) 2017-08-31
JP2017137339A (ja) 2017-08-10
AU2017268634A1 (en) 2017-12-21
AU2020201297A1 (en) 2020-03-12
AU2012342117A1 (en) 2013-05-30
SI2782598T1 (sl) 2020-12-31
HRP20201282T1 (hr) 2020-11-13
DK2782598T3 (da) 2020-08-10
CA2856255A1 (en) 2013-05-30
CN108864291A (zh) 2018-11-23
KR102274211B1 (ko) 2021-07-09
PL2782598T3 (pl) 2021-03-08
JP2019146576A (ja) 2019-09-05
US11198716B2 (en) 2021-12-14
US20180162917A1 (en) 2018-06-14
US20140248302A1 (en) 2014-09-04
CN104066447A (zh) 2014-09-24
JP6121436B2 (ja) 2017-04-26
RU2650574C2 (ru) 2018-04-17
RU2018108421A (ru) 2019-02-25
CN108864261A (zh) 2018-11-23
CA2856255C (en) 2021-06-22
EP3744343A1 (en) 2020-12-02
MY184576A (en) 2021-04-06
WO2013076580A2 (en) 2013-05-30
EP2782598A2 (en) 2014-10-01
KR20190112161A (ko) 2019-10-02
AU2012342117A8 (en) 2014-07-03
US20160207972A1 (en) 2016-07-21
JP6570081B2 (ja) 2019-09-04
EP2782598B1 (en) 2020-05-27
JP2022023081A (ja) 2022-02-07
IL279676A (en) 2021-03-01
MX2014006232A (es) 2015-02-10
BR112014012460B1 (pt) 2021-01-12
JP7470669B2 (ja) 2024-04-18
JP2014534258A (ja) 2014-12-18
IL232645A0 (en) 2014-06-30
KR102024066B1 (ko) 2019-09-24
MY188083A (en) 2021-11-16
US20220153798A1 (en) 2022-05-19
WO2013076580A3 (en) 2013-08-22
LT2782598T (lt) 2020-07-27
KR20140108235A (ko) 2014-09-05
AU2017268634B2 (en) 2019-11-21
HUE050438T2 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
IL279676A (en) Recombinant proteins and therapeutic uses
IL260045B (en) Polypeptide structures and their uses
HK1243427A1 (zh) 治療肽
IL230918A0 (en) Modified proteins and peptides
HK1200489A1 (en) Recombinant human naglu protein and uses thereof naglu
HK1192587A1 (zh) 治療性融合蛋白
EP2738255A4 (en) PEPTIDE FROM ERAP1 AND ITS USE
EP2711376A4 (en) FGFR-FC FUSION PROTEIN AND USE THEREOF
PL2668205T3 (pl) Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
SG11201404180RA (en) Cho-gmt recombinant protein expression
EP2762149A4 (en) PEPTIDE DERIVED FROM ERYTHROPOIETIN AND USE THEREOF
EP2734543A4 (en) LACTOFERRIN FRAGMENTS AND USE THEREOF
HK1211952A1 (en) Recombinant protein
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides
GB201121236D0 (en) Proteins and peptides
IL230474A0 (en) Lactoferrin segments and their uses